jNeuroKids ll .tJ Table of contents › wp... · Movement disorders # Cranial nerves disorders...
Transcript of jNeuroKids ll .tJ Table of contents › wp... · Movement disorders # Cranial nerves disorders...
jNeuroKids l
l .tJM
Table of contents NeuroKids r'6
A Emergency and intensive careA.01 Febrile seizures
A.02 Status epiLepticus (SE)A.03 Acute dystonic reactionA.04 Acute Ataxia
A.05 Acute increased intracraniaL
pressure (ICP)A.06 Guillain-Barre Syndrome (GBS)A.07 Neurometabolic dysfunctionA.08 Traumatic brain injury (TBI)A.09 Paediatric stroke
A.09.1 Thromboembolic events
A.09.2 IntracraniaL
haemorrhage/bLeedingA.09.3 CerebraLvenous sinus
thrombosis
A.09.4 Dissedion (cerebrovascular)A.0(;).5 Arteriovenous
malformations
A.10 Battered child
A.11 Coma
A.12 Brain death
A.13 Intoxications
B NeonatologyB.C)1 NeonataL seizures
B.02 NeonataL hypoxic-ischaemicencephalopathy (HIE)
E Epilepsy
E.01 EpilepsyE.02 First seizure
E.03 ParoxysomaLevent»(non-epileptic)E.04 West-SyndromeE.05 Benign epilepsy with
centrotemporaL spikes (BECTS,RoLandic epitepsy)
E.06 Absence epilepsyE.07 JuveniLe myoclonic epiLepsyE.08 LocaLizing signs in epilepsyE.09 Therapeutic strategies in
different electroclinicaL epiLepsysyndromes
E.10 EpiLepsy surgery
F Vertigo
F.01 Vertigo and dizziness
G Movement disorders
G.01 CerebraL palsyG.02 Dystonia
H Cranial nerves
H.01 FaciaL patsyH.02 0ptic neuritis
I RehabiLitation
I.01 Rehabilitation (inpatient)
N Neurometabolic and
neurodegenerative disorders
N.01 NeurometaboLic disorders
N.02 Neurodegenerative disordersN.03 Mitochondrial disorders
0 Neuromuscular disorders
0.01 Neuromuscular disorders
0.02 Muscle dystrophies0.02.I Duchenne-Becker
muscular dystrophy(DMD, BMD)
0.02.2 Limb-girdle musculardystrophy ( LGM D)
0.02.3 Emery-Dreifuss Syndrome0.02.4 Myotonicdystrophy,
Dystrophia myotonica (DM)0.02.5 Facio-scapuLo-humeraL
muscular dystrophy (FSHD)0.02.6 DistalmuscuLardystrophy0.02.7 Congenital muscular
dystrophy (CMD)0.03 Myopathies0.04 Myositis0.05 SpinaL muscu(ar atrophy (SMA)0.06 NeuromuscuLartransmission
0.07 Peripheral nerve lesions0.08 Neuropathies
C Pain
C.O'l Headache
C.02 Primary HeadacheC.03 Secondary HeadacheC.04 Pain managementin paLLiative careC.05 Idiopathic intracraniaL
hypertension (IIH)
D Development
D.C)I Deve(opmentaL disordersD.02 Hyperkinetic disorderD.03 Education entrance qualification
(schooL maturity)D.04 Tic disorder and Tourette
syndromeD.05 Autism spectrum disorder (ASD)D.06 FetaLaLcoholspectrum disorders
(FASD)
J Inflammation and infection
J.01 MuLtipLe sclerosis/ADEMJ.02 CerebralvascuLitis
J.03 Lyme diseaseJ.04 Meningitis and encephalitis
K Oncology
K.01 Neoplasm ofthe CNS
L Genetics
L.01 Genetics
L.02 Neurocutaneous syndromesL.03 CraniosynostosisL.04 RettsyndromeL.05 Microdetetion syndromesL.06 Trisomy 21
M Autonomic nerve system
M.01 HypersaLivation and dysphagiaM.02 BLadder dysfunctionM.03 Sleep disorders
P Hydrocephalus, Myelomeningocele(MMC), Chiari Malformations
P.01 Hydrocephalus in infantsP.02 Management ofthe shunted
hydrocephaLusP.03 Myelomeningocele (MMC)P.04 Chiari maLformations (CM)
Q Neuro-Orthopaedics
Q.01 HipjointQ.02 ScoLiosis
R Neurological examinations
Medication
4/11
mNeuro,.dC:-)1d iPad Screenshots NeuroKids
mNeuroNls
it.iWKoh'ha""a'
iPad 9 16:09 '?Lädtnich}?')
IIEGet Access
Preface
How to use this app
Abbreviation
List of Authors
Support Groups
Notifications
Feedback
Cooperation Partners
Imprint
r NeuroKids
C' Emergency and intensive care
Neonatology and perinatolügy
la Pain
Developmental neurology and psychiatry
&
II
1
NeuroKidsl
j
11
j
"lr.
Kohlhammerl?
iPad 9 lSupport Groups
Get ACCe'iS
Preface
HOW to use this app
Abbreviation
List of Authors
Support Groups
Notifications
Feedback
Cooperation Partners
Imprint
r NeuroKids
l Q
Emergency and intensive care
:' Neonatology and perinatülogy
Pain
Developmental neurology and psychiatry
1l1I
i
r' i i ir+f' roups'%l l l UlA p p Ilj l
A: Emergency and intensive care
A.01 Febrile seizure, see chapter E
A.02 Status epilepticus (SE), see chapter E
A.03 Acute dystonic reaction, see chapter G.02
A.04 Acute Ataxia:
Ataxia UK
Lincoln House
Kcnninqton Park1-3 Brix}on RoadLündon. SW9 6DE
Great Bri!ain
Phüne: +44-'20 7!i89 1444
Fax: +44-20 7582 9444
Homepage: www.ataxia.org.uk >
A.05 Acute increased intracranial pressure (ICP), see chapter P jA.06 Guillain-Barre syndrome (GBS):
nP": IrlnP Fril indaliOn In{erna{ional
The Holly Building - 104 142 Fotrest Avenuel'irbprth, PA. tqnzz
uSAT?snone: + 610-667-0131
Fax: +1-fün-667-7036
Home(»aqe: wwvii.qbs-cidp.orq >
r.Al>I? ri iilhin-F!attti & A'ssori lmaföry %eli7pri.Jliie6
5/11
iM
iPad Screenshots NeuroKids
l iPad ?
<
?A.01 Febrile seizures
Q
. ....'. Diagnosis
. .."' Therapy
is:og
A.01 Febrile seizures
Diagnosis
""]-; r
»yalaal
?0;+..i..-. Css[bXlib?uilvwl
C?
r?*bmea:ia?l
lag*&almall-a--?li??
?Lädtnich(?)
[03
-41%-€-14
OIM 4%%I!
Iw«0lW*OWaiml
l DiagnOSiS Therapy i
6/11
mma
s2W
iPad9 16109 Lädtmch}i
NeuroKids = JL]e
Emergency and intensive care
l
Neonatology and perinatology
"@@Pain
Developmental neurology and psychiatry
Epilepsy
Vertigo
Movement disorders
#Cranial nerves disorders
Rehabilitation
Inflammation and infectious diseases of
' the central nervous system -
Oncology "" '
Genetics
&Disorderoftheautonomic nervesystem @ ,: Neurometabolic and neurodegenerative
disorders
T. nxn2,k
Imm0
QJ
NeuroKids
»-fi/d iPhone Screenshots
mNeuro,,.1s
NeuroKids N
ffl 'lGet Access
Pre1ace
How to use this app
45576viation
l ist of Authors
Support Groups
Notifications
Feedback
roopsration Partners
Imprint
F€
r4.0j pB5(%le seizures ]
$1
lDiagnosis
Thetapy
r @@@@@ Tele)om.de 9
(Back
16:02 lla:)(
3
Support Groups
A: Emerqency and intensivecare
A 01 Fpbrilp qpi'iure, see chapter E
A.02 Status epilepticus ISE), seechapter E
A O! Acute dystonic reaction, seechapter G.02
A 04 Acute Ataxia:
Aiaxia UK
Lincoln Housem?Kenning}on Patk
1-3 Brixfön Road
l ondon oWa c
Greai Bri(ain
Phone: +44-20 7582 1444r- {I aa'yrnav'?x 4
Homepage: ICli u >
A 05 Acute iricreased intracranial
pressure I?CP? epp rhaptpr P
rlll
l
iri
r
Ü. I61fü
(BackA.01 Febrile seizures
Diagnosis
?..«?w*#
%?(
I??
'1.»"';l
s
8/11
*****Telekom.de"' 16:02 (Wll
( A Emergency and intensive care ffi
I -=-=-=-l -=-=-=-=-
Acute iiicreased intyacranial
' " pressure(ICP)
.. .' Guillain-Barrö Syndrome (GBS)
l -------=-=-=-=-l =-=-=-------=l =-=---------
*.sx ':.v
00000 Telekom.de 1 18:02 'T {-k
A.01 Febrile seizures<3ack Thetapy 'E.
x
(.on}inuing seizute:
k Midazolam @ IV 0;l-0.2 mg7kg/single dose
O(
k Lorazepam @ IV O,C6-0,1 mg}kg/single dose
or
> Cnazepam @ 0,25 mg7kg/single dose
In case o} continuing SelZu(e:
s Phenoba+biLal @ IV 10 mg/kg/single dose
hhs*sTelekom.de a I8:02 4 '-]D+
A.01 Febrile seizures<BaCk üiagnOSlS Y
......,..,....=...,....,,.,.,.,.1testing; ij negative: SCN9A and PCDH19)
mNeuro,Idc
J Workbook sample pages
Medication
A
Acelazolamide IAZAI
DoaaHe:
» rpiltpxy:8-}Omgjkgld(axxtattdintheSummxryo[Pyodu«tChyat«ei!xikx.SPCl» «ype 2 epixt»dlt a«ixxix: 5-10 mglkgJd ko[[-föbxllb :d!opathic imrxcyanixl hyptvitnsksnlpxtudoiumoy cvrtbvi {o[[-Ixbtll
- !n{xmi: initixl doxt 8 mgJkgJd tt 3 xxpux«r doi?ey. intvtaxe il yequ!red lo amaximum o{ 100 mgJkgldthiklven: xtxvi iviih .)5 mgJk(}d, in«yxair by 25 mglkpJd il ttqu!ytd(max. 100 iiig}kg{d ov ! Jd)
? adolexctiiis: xiayt with 25 mg%yJd. in«yeaye by )5 mg+kzld i[ trquitxd(max. 100 mglkgM ö} 2 g{d)
b «rnml yrxpiyatory dixoydxr wiih attompxnying hl'poxxm!a: 7.5-lü.0mJkg{dItau«!on: mr«abol!t dvtompenyx«!onl
Nvumpavd!a«vlc iiidiciitioiit:
yvduttion ot tryebyoipinal nuid ICSP) pyodut«ioii rritli iiitrtxx« ol !n«ta«yxnialpyxxxuyt (ICP) (intmdiiig poxilirmt?yyhxgi« vxn«y!tulxy d!Ix«ütion and idlopx{h!«:niyatnnW liyptt«eny:onlaltrynziive thrtapy [ot pmlal. genxyaliud oy slixvntt epiltpq {ihoit?irtm)
- typr 2 tp!xod!c a{xxix? «tnu?xl ttipitato«?y dixoydey wilh ati:ompxiiyinB hypoxrmia
Mechan!ym ol acr!on:
- «aybonic anhydyxxe iiihibilor
Relevank wiirva!iid!xak!onx:
? hypokxlvm!a. hypona{yemix
Re{evaiix y!de elleay hnd !mevacr!anx:
mvlxbolik iv:idoy!s
1»?vqueiil uiiiiülioiitkin raxh
payry{hvxixliypvy«xltiuvixlnxphmlithixxii
?- nvphmtox!t in tomb!nn{!on wi{Is NSAIDi-:n«iiixye ö( Csybamxzvp!iit Ixvrl
Inyvly) Sixvvny4olmxon iyndtomr
*ppniml swui: -
Souicvy:
G*rmxsy - IPC: -U%A - Tl
- *puvpx'rxnl
l- 10 mH%ld u l-i xqyyyi* dag*a. #01 is «x*d )n mlJld ny l dl: tmn)tl wlxut oygffl* 10 001«*asxx*sl*d (O( u*gm*n« ni *yX«yii
«]ss*
- oTh 0( IV
?. isH%ldagalDn«likmdmahluyXDus:l*d K!aHd*x - BNO{?:
- *yN*pay
- 04ffl 01 h} Ob# 1011{Ok%0%X i%lKliNk
?. s**sai*: ixi«W )ny« !3 m(% !-) iimtx ]y:li: mglm*ass* dosv }J mHlky }-I iimn ]yXi? ahlldza l mnülh-I} y«yy: Ixl«id du* 1.1 sHlkH l-] «lmvg nxili. lö%nia«d }} }-l m)IJ
)-l üm«x J01ly. m+x. 150 mHld {mxuu*xgxb dnxl. ahllAr*x ?l-111 }00I0: !}0 111! !-l lim*x (hi!i
? xbal Ixi*a*sW pr«zz*yv- saal 00 Ly alss ini+mxniiy ixjt«iinn
- ahlkla*n l monlh-I} l'vxry: ixlW Jl)I} 0 *H% i 1:00(0 flally. Ix«inxisH yx xv«vxxyq in föL}.l(X my%ld
Commim:
? «xix[ul uyv o[ loiig tanii xdmiiiixmtion? [yrqurni «on«tol o[ x«!d-füxt homroxtsiix äl wrll !I rlxayt?lyivs
Acetylsalicylic acid iASA)
Dosage:
» y«yokr prophylaxiy: l-) mgJkyJdiiiitial doxv [ot x«u«x x«yokr matmrnt ay iii xut of ttmpnvxq xymptomx:3-5 mglkgld liiitoi'i+ialion only [oy xdul!y xva!lable. +iüt [oy fhildyenl
? x{itv 3-6 mo+ilht üt LMWH «rrmpy [olliiwiiig thi tliiiitally acutt phxx+. in iixixblt tinnatioii: )-5 mglkgld Ino mföi'mttion on doxxgt xiid tolziföi!ity or ASAavxilablt lot iitwbotiis)
b acuie ttnx:on-typr htxaatiie Ire!Imenll 10-15 mg}kg p.o.rw» a«ute migiaine tytütmtm: 10-15 mgAg p.o.+Wb m!gnine pyophylxxix: 2-3 mgJk(}d p.o.b Kawxxaki ilixeaxt with [evrv: }O mgJk0d ov Hü-100 mlkgM üs 4 xtpiüalt doxrx
OVky 48-72 11. WlöWkd liy 3-} mdkdd: diXkön{!niie {Ik!{men{ ni{el 6-8 WkkkX
A
39I
Nxurophed!akv!x !ndlcm{!ony:
?- py:msiy snd xrtondxi?y x«yokr pyxveii«!onlpvophylnxixt«niion-typ« lirnds«hräCull mig[&ine I}lflmlnl
? migyaine piophylaxiy-Kxwxnkl diiexxe
Michanitm ol nc«ion:
-inhibition o[pls«elrt üggiigütion föiough iiiliföitioii o( tyclo-üxygenxyr with «onxr-cu{!v« txdu«{!on oi {litomboxxne A2 üiid piiiitacltlin iy'rahexii
Relevant comya!nd!cak!ony:
ievryx livrt oy yrnxl [xiluye
«hildyrn and xdolrxcrnrx w!{h ixvvr!xh illiitxy
Relevünl x!de ellecky and !nlevacklonx:
-vxyy T!Il al low doxv? nauxn, lieay{buyn. vomiling
b»?t?ncho«onxtyn:t!on
mu«oial iriitatioii. y,axtyoimeyunsl lileiding and prpi!t ul«rryelxpxe oi Ichyon!t) !nnammstovy bowrl dixxxyxyRrye xyiidyomt iii «h!?dven (tnd xdoltittmi} wilh l'xvrviyh illnryx {liix{oy!«xl)
Appioval skakuy:
varirs dipending on pyodu«l (100 SPC)
Souvces:
Gsrmyny - SPC:
FIlJll{I[mI==-=-
Tkr !D yyx I»« Hlg*s *g*q ?l-% k. if a*a*saq.Uu - T:
- v.isyxx{l J!wxw
- nrffl
- 00-l W rx%lkdd nm)sl :010 ?l d04s. l.(. }N=} %Wlt. N]mWXlll[] }OOIY ! } iöl 00 In l ?l d {%nl!I@?[I 4[Xölvk! iö4 01 10041 nt h}: IL40 k44044 Th0 !W 10 )-} m%lJhl N%kk d[lly. fö [!li[OV401(xö%{ kk4kk0ff On0ff OLsa%.d:{140. 00011000 4011% Th} lö40 ]öK {01 k-[ #}}}}. fö [%{1001{ !Kilhtn«nsyq ggi*q gLa*?fflii:*a. wffabia Il+ las.]nyy Ir«ykmtm isdthi«yly liü yddllios In ILv«gyy-(:fö Wsrla«la}.
%l- iahki. :.(. +I0 mHW11-) IOLl0u. i.a. }Ok-110 In%
llll
yaxlH**la-. aTh, r*alsl. IV
- 10-I} *H% *?q l -t h. %%. ÄO%l l %Mynl:?:slbssx*lsq- s«ffl
- :s:»Wli: !k-% xylkHld flia:d*d 101(l +g««ffl )vy«x
. 4140ffl #0:%{Oaa%00 d04# [0-I» %%l[%ld %i0kk i0 [[[lOHvlN )kTOl NOkq k-% 11- **aiis« -{XA g*41'0% ?I%44n%%%0
- y»{lyW*W *fi*au
g)sl*g«* pg*fl:ania g«*d:*a hga* 001 'x*s ?+«lam*d: yy*]iy!ylv dnxyy* ix )*«ia*d lynm ad«]l g{*dlag00} d:a:*l *ap*ri*aa* asl ü #01 »a*% *g«a}Ilgl?
- %H*gid dag*g hga* «gaypd }0## l-i sylkHld io I-10 mHfl-yl { yx t XD. D«*y y< l) plo%i g**sd*]
- ?04!Ol !%hss!0 01(0100, 400%#0%ll l i ?I{dl N[ f XD [llkl !Nlikö[{vl[llk% I}[40Ji Is4 Is00):s*i»i:a**).
Um!? KlsH]aw - &Nr'C:- KxwxsxlU IIM?K
? 0föl
xvnxy{vx: ixliUy 11 mHl{vll u ?l xtym«g«* J***a is« ) »a**l.a 0( 001:l aivLill«. {olhasvl }} } ixy%ld {T ! XD hsi k-[ s«kx: il iin w:d««* ni as«saaq I*a:*aa gl{*« [ s+la. ]ia«nxiixv« u*y«myxi nrx««y *?i« y(Ivkt«hll)r*n l movah- 11 yexu: :alb%y }0-1% *y%ld ag l #yaT010 hlly n««x lög l «a*«{x 01 vi»iilyl*L«ll«. fö0N !-I mlkHld sg a (D im k-x »a**ü :+ i»* *a:]**av *{anrnnx'- I*xlanx yl«ty [ #0*k!.nix«oxiinvy «inim*xt or x«k *xy*n gda:a*
? Inblbllfön ö( plyl? ygpvHxi!ns. yha*si!ss s[ Th«s*{ga L*«m*ilsn *ll«y «ydü« xvvHvq- oad
- x«nyl«x:l-laaH%l)axglD- «hlldy*n l mnsTh- l) l*m: l-i mH%)d Isg*ffl isax. :I m0 01 t (D- ahlMbü I}-va ybgy: )l sHld 11( a ID
IV «ommen{:
? incyessxd (potent!allylh!ytoyicxll i?itk ol dvvxlopiiig RIYI yyiidromt (< 12 ymy)yhould not bi xdminiiteyxd diiting xcu«e Lrliyile d!yexyt (vxpeaally vayittlla dii«urxnd :nlluinza)
- üpiiontl monito+ing ol xmi«ox@ulx«ion: plxreltt {un«tion ittiing
A
392
10/11
INmmmm
mElmmg